Treatment with pentoxifylline in Behçet’s disease

Soares, Rui Oliveira; Freitas, J. P.; Ramalho, Pedro; Rodrigo, F. Guerra

doi:10.1046/j.1468-3083.2002.00392_8.x

Cited by 6 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, recurrences occurred in all patients after discontinuation of treatment. Pentoxifylline has also been described as alternative treatments for ocular lesions in few patients with BD [75, 76]. Sulfasalazine (2–4 gr/day) was reported to be an effective choice for the treatment of gastrointestinal involvement [77].…”

Section: Treatmentmentioning

confidence: 99%

New Evidence-Based Treatment Approach in Behçet's Disease

Alpsoy

2012

Pathology Research International

View full text Add to dashboard Cite

Behçet's disease (BD) is a chronic, relapsing, and debilitating systemic vasculitis of unknown aetiology with the clinical features of mucocutaneous lesions, ocular, vascular, articular, neurologic, gastrointestinal, urogenital, and pulmonary involvement. The disease is much more frequent along the ancient “Silk Route” extending from Eastern Asia to the Mediterranean basin, compared with Western countries. The disease usually starts around the third or fourth decade of life. Male sex and a younger age of onset are associated with more severe disease. Although the treatment has become much more effective in recent years, BD is still associated with severe morbidity and considerable mortality. The main aim of the treatment should be the prevention of irreversible organ damage. Therefore, close monitoring, early, and appropriate treatment is mandatory to reduce morbidity and mortality. The treatment is mainly based on the suppression of inflammatory attacks of the disease using immunomodulatory and immunosuppressive agents. In this paper, current state of knowledge regarding the therapeutic approaches is outlined. To provide a rational framework for selecting the appropriate therapy along the various treatment choices, a stepwise, symptom-based, evidence-based algorithmic approach was developed.

show abstract

Section: Treatmentmentioning

confidence: 99%

New Evidence-Based Treatment Approach in Behçet's Disease

Alpsoy

2012

Pathology Research International

View full text Add to dashboard Cite

show abstract

“…It has known to reduce the levels of inflammatory mediators including TNF alpha, interleukin 1, interleukin 6, and interferon‐gamma levels 24 . There are several reports suggesting pentoxifylline as a safe option in the management of mucocutaneous, ocular, and intestinal involvement of BD 25‐28 . It has been hypothesized that pentoxifylline may also reduce tissue damage during the cytokine storm host response to SARS‐CoV‐2 infection 24 .…”

Section: Treatment Considerations For Patients With Behçet Disease In...mentioning

confidence: 99%

“…24 There are several reports suggesting pentoxifylline as a safe option in the management of mucocutaneous, ocular, and intestinal involvement of BD. [25][26][27][28] It has been hypothesized that pentoxifylline may also reduce tissue damage during the cytokine storm host response to SARS-CoV-2 infection. 24 Considering, its favorable profile of safety and tolerability, pentoxifylline may be considered a potential treatment option for the management of recalcitrant cases of BD in the era of COVID-19 pandemic.…”

Section: Pentoxyphillinementioning

confidence: 99%

Treatment considerations for Behçet disease in the era of COVID ‐19: A narrative review

Elmas

Demirbaş

Bağcıer

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

COVID‐19 is a multisystem disease caused by severe acute respiratory syndrome coronavirus 2. It has been declared a pandemic by the World Health Organization in March 2020 and the outbreak still keeps its impacts worldwide. Behçet disease (BD) is a multi‐systemic vasculitis involving the skin, mucosa, eyes, joints, nervous system, cardiovascular system, and gastrointestinal system. The precise etiopathogenesis of the disorder is unknown but autoimmunity is believed to play a key role. A considerable part of patients with BD are susceptible to immunosuppression and are more predisposed to infections than healthy individuals. Hence, the protection and control measures for patients with BD against the COVID‐19 are of the utmost significance. Given the requirement to balance proper treatment of BD with the smallest risk of COVID‐19 associated mortality and morbidity, we aimed to review the management of BD in the era of the pandemic with a special focus on treatment considerations. According to current expert recommendations, there is no reason to discontinue topical treatments, colchicine, and nonsteroidal antiinflammatory drugs. Systemic steroids can be used at the lowest possible dose if needed. Ongoing treatments can be continued unchanged in patients with no suspected or confirmed COVID‐19. In cases with COVID‐19 symptoms, immunosuppressive and biological agents can be temporarily stopped but the decision should be made on a case by case basis. Considering their potential beneficial effects on the course of COVID‐19, colchicine, pentoxifylline, and dapsone can be considered as safe treatment options in BD.

show abstract

Maladie de Behçet

Boulinguez¹

Manifestations Dermatologiques Des Connectivites, Vasculites Et Affections Systémiques Apparentées

View full text Add to dashboard Cite

La maladie de Behçet (MB) est caractérisée par des lé-sions de vasculite plurisystémique d'étiologie inconnue. La MB avait été décrite dans les traités d'Hippocrate (chapitre VII du troisième livre des Épidémies) comme une maladie endémique en Asie Mineure caractérisée par des aphtes, des lésions génitales, des lésions ophtalmologiques chroniques qui rendaient aveugle et des lésions herpé-tiques larges. Il fallut attendre le XX e siècle pour qu'un dermatologue turc, Hulusi Behçet, en 1937, décrive une triade symptomatique associant aphtose buccale, aphtose génitale et uvéite à hypopion. Cependant six ans auparavant, Adamantiades, médecin grec, avait rapporté une observation similaire. La MB est parfois appelée maladie d'Adamantiades-Behçet dans la littérature. Ubiquitaire, l'incidence de la MB varie considérablement selon les régions du monde. Elle est plus élevée le long de la « route de la soie » (du pourtour méditerranéen au Japon) que dans les pays occidentaux : 80 à 300/100 000 en Turquie ; 10/100 000 au Japon, en Corée, en Iran, en Arabie Saoudite ; 0,6/100 000 au Royaume-Uni (Yorkshire) et 0,1/100 000 aux États-Unis ¹-³. Les cas autochtones sont de plus en plus fréquents en France ⁴. Manifestations dermatologiquesAphtose buccale Selon les critères diagnostiques utilisés, l'aphtose buccale est présente dans 90 à 100 % des cas de MB. Elle est inaugurale dans 25 à 75 % des cas et peut rester longtemps isolée ⁵-⁷. Il est impossible cliniquement de différencier les lésions buccales de la MB des lésions d'aphtose récidivante idiopathique ou d'aphtose complexe que ce soit sur le sexe, l'âge de début, le nombre de récidives annuelles, le nombre de lésions au cours de chaque poussée et la durée de gué-rison ⁸. L'aphtose buccale est un critère dont la présence est exigée par les critères diagnostiques internationaux du Study Group for Behçet's Disease ⁹ (encadré 7.A). Les aphtes sont des ulcérations douloureuses, isolées ou multiples, à bords nets (à l'emporte-pièce), au fond « beurre frais » ou grisâtre, entourées d'un halo inflammatoire. Ils siègent sur la face interne des joues, le sillon gingivo-labial, le pourtour de la langue ( fig. 7.1) et le frein, le palais mais aussi plus rarement sur les amygdales et le pharynx. Classiquement de forme arrondie ou ovalaire, ils peuvent prendre une forme linéaire ( fig. 7.2) notamment dans le sillon gingivo-labial et au niveau de la commissure rétro-molaire. La taille varie habituellement de 1 à 10 mm. Les lésions géantes sont rares. Le nombre d'aphtes au cours d'une poussée varie de

show abstract

Treatment with pentoxifylline in Behçet’s disease

Cited by 6 publications

References 2 publications

New Evidence-Based Treatment Approach in Behçet's Disease

New Evidence-Based Treatment Approach in Behçet's Disease

Treatment considerations for Behçet disease in the era of COVID ‐19: A narrative review

Maladie de Behçet

Contact Info

Product

Resources

About